Apotex announces launch of the Apotex Global Health Access Fund to promote health equity with $250,000 in annual funding to the Rexdale Community Health Centre
Dec 10, 2024Toronto, Ontario - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced the launch of the Apotex Global Health Access Fund to support programs that promote health equity and address the root causes of health disparities.
Building on Apotex's legacy of giving, including Apotex's global medicine donation program, the Apotex Global Health Access Fund launches with a focus on addressing unequal access to care and low health literacy within communities where there are poor social determinants of health, and where race, economic status, and other factors are barriers to access.
In its inaugural year, the Apotex Global Health Access Fund will focus on funding maternal health programs in Canada, the United States, India, and Mexico with an annual budget of $1 million.
The first recipient of an Apotex Global Health Access Fund grant is the Rexdale Community Health Centre (Rexdale CHC) in Toronto. The Rexdale CHC will receive $250,000 annually over three years to support prenatal and postnatal programs, with a focus on providing much-needed wraparound services to the North Etobicoke community in its clinics and through its recently launched Mobile Health Clinic.
"We are thrilled to launch the Apotex Global Health Access Fund, which underscores our commitment to addressing health inequities and supporting the most vulnerable populations in our key global markets. By focusing on maternal health in our first year, we aim to make a significant impact on the well-being of mothers and their families," said Allan Oberman, President & CEO, Apotex. "The Rexdale Community Health Centre plays a key role in delivering much-needed health services to North Etobicoke residents. As we celebrate Apotex's 50th anniversary, we are honoured to contribute to our local community, and to provide opportunities for our colleagues to do the same."
"We are honoured to be the first recipient of the Apotex Global Health Access Fund. This support will enable us to enhance our maternal health programs and provide critical services to the women in our community. Together, we can work towards a future where every mother has access to the care she needs," said Safia Ahmed, Executive Director of Rexdale Community Health Centre.
For more information about the Rexdale Community Health Centre, please click here.
About Apotex
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceutical products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at www.apotex.com.
Media inquiries: Contact Apotex Media, media@apotex.com
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 23, 2025
Apotex Receives Health Canada Approval for LOQTORZI® - The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer
Toronto, ON - October 23, 2025 - Apotex Inc. ("Apotex" or the "Company"), the largest Canadian-based pharmaceutical company, today announced that Health Canada has granted a Notice of Compliance (NOC) for LOQTORZI® (toripalimab) for the treatment of nasopharyngeal carcinoma (NPC), an ultra-rare and aggressive cancer.
-
Oct 8, 2025
Apotex supports launch of home-based cancer care with $1.5M donation
Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
-
Oct 7, 2025
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Searchlight Pharma Inc.(“Searchlight”), Apotex Inc’s (“Apotex”) Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.